Image
CME Snap Shot

Anemia in Chronic Kidney Disease

New Avenues to Improve Patient Outcomes

Clinical Management Guidelines 

Drug safety communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease.

US Food and Drug Administration. Updated August 4, 2017. Accessed November 3, 2022. 

Patient Resources 

Informational resources for patients who have anemia and chronic kidney disease. 

Anemia in chronic kidney disease.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 

Suggested Readings

Overview, Epidemiology, Pathophysiology 

The influence of inflammation on anemia in CKD patients.

Gluba-Brzόzka A, et al. Int J Mol Sci. 2020;21(3):725.

Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States.

St. Peter WL, et al. BMC Nephrol. 2018;19(1):67.

Vadadustat in patients with anemia and non-dialysis-dependent CKD.

Chertow GM, et al. N Engl J Med. 2021;384(17):1589-1600.

Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study.

Fishbane S, et al. J Am Soc Nephrol. 2022;33(4):850-866.

HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.

Haase VH. Hemodial Int. 2017;21(suppl 1):S110-S124.

A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps.

Lopes MB, et al. Sci Rep. 2021;11(1):1784.

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Pfeffer MA, et al; for the TREAT Investigators. N Engl J Med. 2009;361(21):2019-2032.

Daprodustat for the treatment of anemia in patients not undergoing dialysis.

Singh AK, et al. N Engl J Med. 2021;385(25):2313-2324.

Singh AK, et al. JAMA Intern Med. 2022;182(6):592-602.

Activity
Burdens of Anemia in CKD

New Avenues to Improve Patient Outcomes

Activity
Pathophysiology of Anemia in CKD

New Avenues to Improve Patient Outcomes

Activity
Managing Patients with Anemia Associated with CKD

Anemia in Chronic Kidney Disease: New Avenues to Improve Patient Outcomes

Activity
HIF-PH Inhibitors for Anemia Associated with CKD

Anemia in Chronic Kidney Disease: New Avenues to Improve Patient Outcomes

Relevant Resources

Incretin-Based Therapies for Type 2 Diabetes

Mechanism-Based Strategies to Achieve Patient-Centered Care

Clinical Updates in Systemic Lupus Erythematosus

Improved Diagnostic and Management Strategies

Insulin Replacement Therapy for Type 2 Diabetes

Patient-Centered Management of Hyperglycemia in Primary Care

Improving Outcomes in Type 2 Diabetes

Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens

A Focus on Bipolar Depression

Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes

Advances in Immunosupressive Therapy for Solid Organ Transplantation

Long-Term Management Strategies to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Clinical Issues in Type 2 Diabetes

Discussions and Debates Around GLP-1 Receptor Agonists

Clinical Issues in Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Improving Outcomes for Women with Type 2 Diabetes

Individualizing Evidence-Based Care

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Improving Outcomes in Congenital and Acquired Lipodystrophy

Best Practices in Diagnosis and Management

Improving Outcomes in Rheumatoid Arthritis

Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

Clinical Issues in Type 2 Diabetes

Consensus and Controversies Around Intensifying Noninsulin Therapy

How Low Do You Go?

Clinical Updates in LDL-C Management

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care

Clinical Updates in Type 2 Diabetes

An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies

Evolving Treatment Paradigms For Rheumatoid Arthritis

Translating Comprehensive Patient Evaluations Into Personalized Therapy

Clinical Updates in Rheumatoid Arthritis

New Perspectives on Targeting Remission and Individualizing Therapy

Raising the Bar by Lowering the Target

Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

A Better Look at Rheumatoid Arthritis

Using Imaging to Improve Patient Outcomes

Clinical Issues in Rheumatoid Arthritis

Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs

Injecting New Ideas into Managing Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Pathways to Better Outcomes in Systemic Lupus Erythematosus

Translating Pathophysiology into Targeted Treatments

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Multidimensional Issues in Type 2 Diabetes

Looking Beyond Hemoglobin A1c

Clinical Issues in Rheumatoid Arthritis

Debates & Discussions on the Evolving Role of JAK Inhibitors

GLP-1 Receptors Agonists in Type 2 Diabetes

Mechanistic Insights and Evolving Treatment Options

Clinical Issues in Rheumatoid Arthritis

The Evolving Role of JAK Inhibitors

Pharmaceutical Economics and LDL-C Management

Implications for PCSK9 Inhibitors in Clinical Practice

JAKi in RA Practice

Unpacking the Evidence for Their Use Today and Tomorrow

Assimilating the Evidence in T2DM

Cardiovascular and Renal Outcomes With SGLT2 Inhibitors

What’s New in Systemic Lupus Erythematosus?

Unlocking Novel Paths to Patient Care

Expert Views on the Changing Landscape in RA

The Increasing Role of JAK Inhibitors

Updates in Systemic Lupus Erythematosus

Unlocking Novel Paths to Patient Care

Swimming Upstream in Severe Asthma

New Pathways to Patient Management

Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up to Date?

A Focus on Clinical Evidence and Guideline Recommendations

Cause for Alarm

New Avenues to the Management of Severe Asthma

Maybe It’s NOT Mechanical Back Pain

Getting on the Fast Track to Identify AxSpA

Finding the Path in Eosinophilic Esophagitis

Interdisciplinary Strategies for Adult and Pediatric Patients

Answering the Call

Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema

Getting Low in Familial Hypercholesterolemia

Reducing LDL-C and a Lifetime of Cardiovascular Risk

Targeting Clear Horizons

Finding the Path in Chronic Rhinosinusitis with Nasal Polyps

Choosing Your Path in Systemic Lupus Erythematosus

From Patient Evaluations to New Targeted Therapies

Buffing Up on New and Emerging ART

A Look at the Changing HIV Playing Field

PrEParing to End the Epidemic

Optimizing HIV Prevention in Primary Care

Making the Call in Heart Failure

Multidimensional Outcomes With SGLT2 Inhibitors